Investigation of Xiyanping and Azlocillin in Treating Acute Upper Respiratory Tract Infection

目的：探讨喜炎平注射液治疗急性上呼吸道感染的安全性和临床疗效。方法：150例急性上呼吸道感染患者随机分为治疗组和对照组，各75例。治疗组给予喜炎平注射液150 mg静滴，每日1次；对照组给予利巴韦林注射液500 mg静滴，每日1次。两组均加阿洛西林2 g静滴，每日1次。对比两组治疗3天后的临床效果。结果：治疗3天后，治疗组总有效率96%，对照组总有效率84%，治愈率分别为87%和68%，两组总有效率及治愈率均有显著差异(P Objective: To explore the safety and clinical effect of Xiyanping Injection on acute upper respiratory tract infection. Methods: To divide 150 cases into treatment group and control group randomly, 75 in each group. The treat- ment group was given Xiyanping Injection 150 mg by intravenous drip, once daily. The control group was given Ribo- virin Injection 500 mg by intravenous drip, once daily. Both groups were injected with azlocillin 2 g intravenously, once daily. The clinical effects after 3 days treatment were compared between the two groups. Results: After 3 days treat- ment, the total effective rate of the therapeutic group was 96%, and that of the control group was 84%. The curative rates were 87% and 68% respectively. The diferences of total effective rates and curative rates between the two groups were significant (P < 0.01). And the relief of symptoms of the therapeutic group was significantly different from that of the control group (P < 0.05). Compared with the control group, the therapeutic group had minor adverse reactions. Conclusion: Xiyanping Injection with azlocillin can significantly relieve the symptoms of acute upper respiratory tract infection without obvious toxic and adverse effect. It is a favorable medicine for the treatment of acute upper respiratory tract infection.